Home Cart Sign in  
Chemical Structure| 2621928-55-8 Chemical Structure| 2621928-55-8

Structure of MRTX1133
CAS No.: 2621928-55-8

Chemical Structure| 2621928-55-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MRTX1133 is a highly selective KRAS G12D inhibitor that effectively suppresses its signaling pathways.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MRTX1133

CAS No. :2621928-55-8
Formula : C33H31F3N6O2
M.W : 600.63
SMILES Code : C(OC=1N=C(C2=C(N1)C(F)=C(N=C2)C=3C4=C(C=C(O)C3)C=CC(F)=C4C#C)N5CC6NC(C5)CC6)[C@@]78N(C[C@H](F)C7)CCC8
MDL No. :MFCD34567005
InChI Key :SCLLZBIBSFTLIN-IFMUVJFISA-N
Pubchem ID :156124857

Safety of MRTX1133

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Related Pathways of MRTX1133

GPCR

Isoform Comparison

Biological Activity

Description
MRTX1133 is a noncovalent, potent, and selective inhibitor targeting KRAS G12D. It occupies the switch II pocket optimally and extends three substituents to facilitate favorable interactions with the protein, resulting in an estimated KD against KRAS G12D of 0.2 pM. MRTX1133 blocks SOS1-catalyzed nucleotide exchange and/or the formation of the KRAS G12D/GTP/RAF1 complex, thereby impeding mutant KRAS-dependent signal transduction. It selectively inhibits KRAS G12D mutant tumor cells while sparing KRAS wild-type cells. MRTX1133 exhibits single-digit nanomolar activity in cellular assays and demonstrates significant efficacy in tumor models with KRAS G12D mutations[1][2].

In Vitro:

Cell Line
Concentration Treated Time Description References
ASPC1 cells 60 nmol/L 72 hours MRTX1133 and afatinib combination showed synergistic effects PMC10502451
SUIT2 cells 60 nmol/L 72 hours MRTX1133 treatment dramatically decreased pMEK1/2 and partially reduced pERK1/2 PMC10502451
PDAC-K cells (2138-K, 3213-K, 1245-K, PANC1-K) 2 µmol/L 8 hours MRTX1133 treatment decreased pERK signaling and upregulates BIM expression in 3D collagen cultures. PMC11532783
PDAC cells (2138, 3213, 1245, PANC1) 0.5 µmol/L 72 hours MRTX1133, even though it blocked ERK1/2 phosphorylation, failed to suppress the growth of these cell lines. PMC11532783
PDAC cells (2138, 3213, 1245, PANC1) 0.5 µmol/L 72 hours MRTX1133 suppressed ERK1/2 phosphorylation and effectively blocked the growth of mouse and human PDAC cell lines. PMC11532783
KPC210-MR cells 1 µM 48 hours To investigate the ferroptosis inhibition mechanism in MRTX1133-resistant cells, results showed that increased MGST1 expression led to ferroptosis inhibition. PMC11536589
AsPC1-MR cells 1 µM 48 hours To investigate the ferroptosis inhibition mechanism in MRTX1133-resistant cells, results showed that increased MGST1 expression led to ferroptosis inhibition. PMC11536589
KPC210 cells 1 µM 48 hours To investigate the anti-tumor effect of MRTX1133 on KRASG12D-mutated PDAC cells, results showed that MRTX1133 induced ferroptosis. PMC11536589
AsPC1 cells 1 µM 48 hours To investigate the anti-tumor effect of MRTX1133 on KRASG12D-mutated PDAC cells, results showed that MRTX1133 induced ferroptosis. PMC11536589
PK-59 5 nM 48 hours To evaluate the effect of MRTX1133 on KRASG12D-mutant pancreatic cancer cells, results showed reactivation of AKT phosphorylation PMC11793007
PANC-1 5 nM 48 hours To evaluate the effect of MRTX1133 on KRASG12D-mutant pancreatic cancer cells, results showed phosphorylation of ERK and STAT3 was inhibited PMC11793007
KP-4 4 nM 48 hours To evaluate the effect of MRTX1133 on KRASG12D-mutant pancreatic cancer cells, results showed KP-4 had slight intrinsic resistance to MRTX1133 PMC11793007
SUIT-2 5 nM 48 hours To evaluate the effect of MRTX1133 on KRASG12D-mutant pancreatic cancer cells, results showed MRTX1133 inhibited phosphorylation of ERK and STAT3 PMC11793007

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Subcutaneous tumor model Intraperitoneal injection 30 mg/kg (twice daily) Twice daily until study endpoint Venetoclax enhanced the efficacy of MRTX1133 in vivo, leading to tumor growth suppression and partial tumor regression. PMC11532783
Mice PDAC mouse models Intraperitoneal injection 6 mg/kg and 12 mg/kg Once daily for 10 days Combination of MRTX1133 and afatinib led to tumor regression and prolonged survival PMC10502451
Mouse KPC allograft model Intraperitoneal injection 30 mg/kg/day Once daily until tumor volume reached approximately 1500 mm3 Evaluate the antitumor efficacy of MRTX1133 alone or in combination with PGG PMC11866490
Nude mice Subcutaneous injection of AsPC1-MR cells Intraperitoneal and intratumoral injection 1 mg/kg MRTX1133 once daily, PKF-118-310 twice a week for 19 days To investigate the inhibitory effect of combined treatment with PKF-118-310 and MRTX1133 on MRTX1133-resistant tumors, results showed that the combination significantly suppressed tumor growth and induced ferroptosis. PMC11536589
BALB/cAJcl Foxn1nu mice SUIT-2 xenograft model Oral 0.5 mg/kg Once daily for 21 days To evaluate the antitumor effect of MRTX1133 alone and in combination with trametinib and fedratinib, results showed the three-drug combination therapy significantly inhibited tumor growth PMC11793007
Mouse HG-PMP xenograft mouse model 30 mg/kg MRTX1133 significantly inhibited tumor growth, reduced cell proliferation, increased apoptosis, and decreased the activity of MAPK and PI3K/AKT/mTOR signaling pathways PMC10704766
Mice KRASG12D mutant xenograft mouse tumor model Oral 30 mg/kg Single dose Evaluate the oral bioavailability of MRTX1133 PMC9948199

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05737706 Solid Tumor|Advanced Solid Tum... More >>or|Non-small Cell Lung Cancer|Colo-rectal Cancer|Pancreatic Adenocarcinoma Less << PHASE1 ACTIVE_NOT_RECRUITING 2026-08-30 Local Institution - 311, Phoen... More >>ix, Arizona, 85054, United States|Local Institution - 309, New Haven, Connecticut, 06520 8028, United States|Local Institution - 301, Lady Lake, Florida, 32159 8987, United States|Local Institution - 306, Baltimore, Maryland, 21231, United States|Local Institution - 308, Boston, Massachusetts, 02114 3117, United States|Local Institution - 310, Boston, Massachusetts, 02215, United States|Local Institution - 314, Grand Rapids, Michigan, 49546, United States|Local Institution - 312, New York, New York, 10065 6800, United States|Local Institution - 303, Nashville, Tennessee, 37203, United States|Local Institution - 302, Houston, Texas, 77030, United States|Local Institution - 304, San Antonio, Texas, 78229 3307, United States|Local Institution - 313, San Antonio, Texas, 78229, United States|Local Institution - 305, Fairfax, Virginia, 22031, United States|Local Institution - 307, Seattle, Washington, 98109 1023, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.66mL

0.33mL

0.17mL

8.32mL

1.66mL

0.83mL

16.65mL

3.33mL

1.66mL

 

Historical Records

Categories